Multiple Sclerosis Clinical Trial
Official title:
To Evaluate the Activity and the Efficacy of Traditional Swallowing Therapy (TST) Plus Neuromuscular Electrostimulation (NMES) vs TST Plus Sham- NMES in Multiple Sclerosis People With Dysphagia
Dysphagia is a disabling, life-threatening symptom that can cause death in Multiple Sclerosis people (pwMS) through aspiration pneumonia. Speech therapists use behavioural therapies (compensatory and rehabilitative) to alleviate such swallowing problems, with limited benefit. Compensatory strategies such as postural changes and changes in food consistency, have been found to be partially effective, especially in patients with mild dysphagia and may be ineffective in patients with more severe dysphagia. The rehabilitative strategies include "no swallow exercises" which aim to strengthen isolated muscles used in swallowing (such as tongue strengthening) and "swallowing exercises" that aim at strengthening all the muscles used in swallowing while executing a hard, effortful, or prolonged swallow. To date, no randomized clinical trials have shown that rehabilitative strategies are effective. Neuromuscular electrical stimulation (NMES), often referred to as electrical stimulation, was introduced as a novel therapy for dysphagia in the late 2001. The principles of NMES in the limb rehabilitation literature are well established. However published protocols applying NMES to swallowing function have shown mixed results in people with stroke and only one study was published on MS people. This will be a double blinded, randomized clinical trial (patients and research staff blinded) with two arms: standard speech therapy plus Active NMES vs speech therapy with Sham NMES. The aim of this study is to determine whether NMES added benefit to a therapy program comprised of standard swallowing exercises in dysphagic pwMS.
Status | Recruiting |
Enrollment | 136 |
Est. completion date | April 15, 2024 |
Est. primary completion date | April 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis: definite MS (Thompson et al 2018) - Stability: recruited subjects must be in a stable phase of the disease, without relapses which induce worsening > 1 point in the EDSS and with an EDSS <=8 - ASHA<6 and DYMUS >2 - Novelty: subjects should not have been trained with dysphagia program in the last 6 month - Mini-Mental State Examination: > 24 Exclusion Criteria: - Dysphagia related to other diseases - Presence of tracheal cannula - Local or general contraindications to the use of equipment for electrical muscle stimulation of the neck - Malignancies or acute inflammation in the anterior region of the neck. - Lack of collaboration due to mental impairment |
Country | Name | City | State |
---|---|---|---|
Italy | Santa Lucia foundation | Roma |
Lead Sponsor | Collaborator |
---|---|
I.R.C.C.S. Fondazione Santa Lucia |
Italy,
Alali D, Ballard K, Bogaardt H. Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review. Dysphagia. 2016 Oct;31(5):610-8. doi: 10.1007/s00455-016-9738-2. Epub 2016 Aug 4. — View Citation
Bergamaschi R, Crivelli P, Rezzani C, Patti F, Solaro C, Rossi P, Restivo D, Maimone D, Romani A, Bastianello S, Tavazzi E, D'Amico E, Montomoli C, Cosi V. The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. J Neurol Sci. 2008 J — View Citation
Ginocchio D, Alfonsi E, Mozzanica F, Accornero AR, Bergonzoni A, Chiarello G, De Luca N, Farneti D, Marilia S, Calcagno P, Turroni V, Schindler A. Cross-Cultural Adaptation and Validation of the Italian Version of SWAL-QOL. Dysphagia. 2016 Oct;31(5):626-3 — View Citation
Logemann JA. The effects of VitalStim on clinical and research thinking in dysphagia. Dysphagia. 2007 Jan;22(1):11-2. doi: 10.1007/s00455-006-9039-2. Epub 2007 Jan 10. No abstract available. — View Citation
Simonelli M, Ruoppolo G, Iosa M, Morone G, Fusco A, Grasso MG, Gallo A, Paolucci S. A stimulus for eating. The use of neuromuscular transcutaneous electrical stimulation in patients affected by severe dysphagia after subacute stroke: A pilot randomized controlled trial. NeuroRehabilitation. 2019;44(1):103-110. doi: 10.3233/NRE-182526. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change from American Speech-Language Hearing Association (ASHA) score baseline at 12 weeks | The mean difference at ASHA score between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent the primary outcome.ASHA suggests that patients should be divided in groups from level 1 (individuals cannot swallow anything safely by mouth) to level 7 (individual's ability to eat independently is not limited by swallowing function | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from Dysphagia in Multiple Sclerosis (DYMUS) scale at 12 weeks | The mean difference at DYMUS score between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia. therapy plus neuromuscular electrostimulation will represent one of secondary outcome.It's a 10 item self administered questionnaire. The answer "yes" is a red flag for dysphagia | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from Fiber-optic endoscopic evaluation of swallowing /Dysphagia at Outcome Severity Scale (FESS/DOSS score) at 12 weeks | The mean difference at FESS/DOSS score between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent one of secondary outcome. FEES is scored using DOSS levels (scored from 7 to 1). In particular, level 7 is consistent with full oral nutrition with a normal diet | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from Mini Nutritional Assessment at 12 weeks | The mean difference at Mini Nutritional Assessment between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent one of secondary outcome. The score is from 0 to 30. The up score represents a normal value | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from the Swallowing Quality of life questionnaire at 12 weeks | The mean difference at the Swallowing Quality of life questionnaire between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent one of secondary outcome. The minimum and maximum score per subscale ranges from 0 to 100, indicating extremely impaired quality of life versus no impairment experienced by the individual | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from Penetration and Aspiration Score at 12 weeks | The mean difference at the Penetration and Aspiration Score between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent one of secondary outcome. The score is from 1 (no penetration) to 7 (severe aspiration) | after 16 sessions of treatment and after 12 weeks from the end of treatment | |
Secondary | Change from Pooling score at 12 weeks | The mean difference at Pooling score between group treated with traditional dysphagia therapy plus sham Neuromuscular electrostimulation vs group traditional dysphagia therapy plus neuromuscular electrostimulation will represent one of secondary outcome. The score is from 4 (no dysphagia) to 11 (severe dysphagia) | after 16 sessions of treatment and after 12 weeks from the end of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |